Improving access to treatments in challenging marketsThe COVID-19 pandemic has highlighted the importance of ensuring a reliable supply of treatments across the globe at Share XImproving access to treatments in challenging marketshttps://pharmaphorum.com/patients/gilead-jirair-ratevosian-treatment-access/
Gilead says Veklury should work against COVID-19 variantsGilead Sciences says its antiviral Veklury should be effective against the new, more contagious COVID-19 variants discovered in Share XGilead says Veklury should work against COVID-19 variantshttps://pharmaphorum.com/news/gilead-says-veklury-should-work-against-covid-19-variants/
Gilead Q3 revenue rise bolstered by $873m Veklury salesGilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment Share XGilead Q3 revenue rise bolstered by $873m Veklury saleshttps://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/
Gilead’s remdesivir finally gets US approvalGilead’s Veklury (remdesivir) has become the first COVID-19 drug approved in the US following a nod from the Share XGilead’s remdesivir finally gets US approvalhttps://pharmaphorum.com/news/gileads-remdesivir-finally-gets-us-approval/
Gilead’s COVID-19 drug Veklury falls short in WHO’s global trialGilead’s Veklury (remdesivir) has failed to produce an effect on hospital stay and mortality in COVID-19 patients in Share XGilead’s COVID-19 drug Veklury falls short in WHO’s global trialhttps://pharmaphorum.com/news/gileads-covid-19-drug-veklury-falls-short-in-whos-global-trial/
EU ramps up supply of COVID-19 vaccine, drugsThe European Commission has taken its advance orders for potential COVID-19 vaccines to more than 1.1 billion, after Share XEU ramps up supply of COVID-19 vaccine, drugshttps://pharmaphorum.com/news/eu-ramps-up-supply-of-covid-19-vaccine-drugs/
Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapyAdding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients Share XTrial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapyhttps://pharmaphorum.com/news/trial-backs-lillys-olumiant-plus-remdesivir-as-combo-covid-19-therapy/
Gilead files COVID-19 drug remdesivir with FDAGilead has filed its COVID-19 drug remdesivir with the FDA, to treat patients with severe disease, under the Share XGilead files COVID-19 drug remdesivir with FDAhttps://pharmaphorum.com/news/gilead-files-covid-19-drug-remdesivir-with-fda/
Pfizer signs deal with Gilead to manufacture COVID-19 antiviral remdesivirPfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is Share XPfizer signs deal with Gilead to manufacture COVID-19 antiviral remdesivirhttps://pharmaphorum.com/news/pfizer-signs-deal-with-gilead-to-manufacture-covid-19-antiviral-remdesivir/
